CareersInvestor RelationsPress RoomCOVID-19
Login
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases & Conditions
  4. Liver Fibrosis – ELF
  5. Assess the Prognosis of Advanced Fibrosis due to NASH with a Simple Blood Test

Assess the Prognosis of Advanced Fibrosis due to NASH with a Simple Blood Test

Clinical Benefits of The Enhanced Liver Fibrosis (ELF™) Test

The Enhanced Liver Fibrosis test is a non-invasive blood test that measures three direct markers of fibrosis. Direct assessment of fibrosis has proven valuable for identifying patients at risk of progressing to cirrhosis and/or liver-related events.

The most widely studied direct marker is the ELF Test which can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker to identify the patients most at risk of progression to cirrhosis and LREs in patients with advanced fibrosis due to NASH.

ELF™ Test Now Included in Multiple Clinical Guidelines

American Association of Clinical Endocrinology logo

American Association of Clinical Endocrinology

  • ELF was strongly recommended in the 2022 NAFLD Clinical Practice Guidelines
  • ELF testing can be incorporated into a clinical decision pathway to identify NASH patients at risk of progressing to cirrhosis
American Gastroenterological Association logo

American Gastroenterological Association

  • ELF was included in the 2022 Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
  • An ELF score of ≥ 9.8 is valuable for prognostic decision making

Why choose the ELF Test?

Characteristics of an Ideal Non-invasive Liver Fibrosis Test

Applicability in Different Patients/Conditions

Adults

Diabetes

Obesity

✔️

✔️

✔️

Economic Health Value

(Cost effectiveness)

Add clinical value

Improve ease and frequency of prognostic evaluation

✔️

✔️

Access

Simple Blood Test

Large Installed Base

✔️

✔️

1. Day J, et al. J Appl Lab Med. 2019 Mar; 3:815-26.

2. Parkes J, et al. Gut. 2010; 59:1245-51.

3. Irvine KM, et al. Liver Int. 2016; 36:370-7.

4. Rosenburg WM, et al. Gastroenterology. 2004; 127:1704-13

5. Nobili, et al. Gastroenterology. 2009; 136:160-7

6. Srivastava A, et al. J Hepatol. 2019; Apr 6: 50168-8278{19}30227-2. doi: 10.1016/j.hep.2019.03.033.

Clinical Benefits of ELF

Ilustración de una enfermera recolectando un análisis de sangre en un paciente

A simple blood test. Any provider. Any lab.

Blood-based tests can readily support high-volume testing, do not require patient access to specialized imaging equipment or highly trained operators, and generally have lower incidence rates of failure and unreliable results reported for imaging modalities.1,2

  • Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.2,3
  • Improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and liver-related events.4
  • Enhance patient management with a blood test that facilitates more frequent prognostic assessments
Literature Compendium

Literature Compendium

This compendium highlights the ELF Test as a prognostic tool in those with advanced fibrosis due to NASH.

Learn more

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

*In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. The test is not for use in the diagnosis of NASH or for the staging of fibrosis.

References
1
Staufer K, et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. United European Gastroenterol J. 2019 Oct;7(8):1113-23.
2
Karlas T, et al. Evaluation of transient elastography (TE), acoustic radiation force impulse imaging (ARFI), and Enhanced Liver Function (ELF) score for detection of fibrosis in morbidly obese patients. PLoS One. 2015;10:e0141649.
3
Patel P, et al. Hepatol Commun. 2018;2:893–905.
4
Sanyal AJ, et al. Hepatology. 2019;70(6):1913-1927.
5
Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6.
6
NICE guideline NG49. National Institute of Health and Care Excellence; 2016.
7

Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;156:1717-30. 

8

Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018;68:305-15. 

Subscription Button Icon

Subscribe to news from Siemens Healthineers USA

Be the first to know about our events, training, and news